Johnson & Johnson Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31)
Johnson & Johnson (JNJ) reported Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) of $1.28 billion for the 3-month period ending 2012-09-30, per its 10-Q filed 2012-11-09.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecrease · last filed 2012-11-09
- Johnson & Johnson other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2012-09-30 was $1.28B.
- Johnson & Johnson other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2012-07-01 was -$1.66B, a 300.48% decline year-over-year.
- Johnson & Johnson other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2012-04-01 was $1.09B, a 27.73% decline year-over-year.
- Johnson & Johnson other comprehensive income (loss), net of tax (deprecated 2012-01-31) for the quarter ending 2012-01-01 was -$2.56B.
- Johnson & Johnson other comprehensive income (loss), net of tax (deprecated 2012-01-31) for fiscal 2012 was -$2.10B.
- Johnson & Johnson other comprehensive income (loss), net of tax (deprecated 2012-01-31) for fiscal 2011 was -$473.00M, a 124.93% decline from fiscal 2010.
- Johnson & Johnson other comprehensive income (loss), net of tax (deprecated 2012-01-31) for fiscal 2010 was $1.90B.
| Period end | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 3 month | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 6 month | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 6 month as first filed | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 9 month | Other Comprehensive Income (Loss), Net of Tax (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|---|
| 2012-09-30 | $1.28B 10-Q · filed 2012-11-09 | -$385.00M derived: sum of 2 quarters · filed 2012-11-09 | $707.00M 10-Q · filed 2012-11-09 | -$1.86B derived: sum of 4 quarters · filed 2012-11-09 | |
| 2012-07-01 | -$1.66B 10-Q · filed 2012-08-02 | -$572.00M 10-Q · filed 2012-08-02 | -$3.14B derived: sum of 3 quarters · filed 2012-08-02 | -$5.01B derived: sum of 4 quarters · filed 2012-11-09 | |
| 2012-04-01 | $1.09B 10-Q · filed 2012-05-07 | -$1.47B derived: sum of 2 quarters · filed 2012-05-07 | -$3.35B derived: sum of 3 quarters · filed 2012-11-09 | -$2.52B derived: sum of 4 quarters · filed 2012-11-09 | |
| 2012-01-01 | -$2.56B derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | -$4.44B derived: sum of 2 quarters · filed 2012-11-09 | -$3.61B derived: sum of 3 quarters · filed 2012-11-09 | -$2.10B 10-K · filed 2012-02-23 | |
| 2011-10-02 | -$1.88B 10-Q · filed 2012-11-09 | -$1.05B derived: sum of 2 quarters · filed 2012-11-09 | $463.00M 10-Q · filed 2012-11-09 | ||
| 2011-07-03 | $830.00M 10-Q · filed 2012-08-02 | $2.34B 10-Q · filed 2012-08-02 | $2.34B 10-Q · filed 2011-08-09 | ||
| 2011-04-03 | $1.51B 10-Q · filed 2012-05-07 | ||||
| 2011-01-02 | -$473.00M 10-K · filed 2012-02-23 | ||||
| 2010-01-03 | $1.90B 10-K · filed 2012-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |